ScreenerHero

IMUXImmunic, Inc.

NAS · US · Healthcare · Biotechnology · imux.com
16.50USD+0.30%Mkt Cap: 225.13M $P/E: —

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap225.13M $
Enterprise Value65.14M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-97.17M $
Revenue/Share—
Last Price16.50 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees100
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS4525EP1011
Valuation
P/E (Trailing)—
P/E (Forward)-6.42
PEG—
EV/EBITDA-0.55
EV/Revenue—
P/S—
P/B1.45
EPS (TTM)-3.46
EPS (Forward)-2.51
52W Range
5.06092% of range17.43
52W High17.43 USD
52W Low5.060 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE1456.20%
ROA-404.01%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-85.81M $
CapEx (TTM)161.00K $
FCF Margin—
FCF Yield-22.83%
Net Debt-154.53M $
Net Debt/EBITDA1.31
Balance Sheet
Debt/Equity-0.09
Current Ratio5.05
Quick Ratio4.97
Book Value/Sh11.10 USD
Cash/Share11.37 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateApr 15, 2019
Splits
Last Split1:10
Split DateApr 27, 2026
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)42.18 USD
Upside (mean)+155.6%
Target Range19.00 USD – 85.00 USD
$19.00+155.6% to mean$85.00
# Analysts11
Ownership
Shares Out.13.64M
Float11.92M
Insiders0.97%
Institutions65.11%
Short Interest
Short Ratio9.8d
Short % Float11.12%
Short % Out.10.51%
Shares Short1.43M
Short (prev mo.)1.59M
Technical
SMA 5014.70 (+12.3%)
SMA 20010.59 (+55.8%)
Beta1.40
S&P 52W Chg18.16%
Avg Vol (30d)149.92K
Avg Vol (10d)177.42K
Technical Indicators
RSI (14)65.5
MACD0.5455
MACD Signal0.3109
MACD Hist.+0.2346
BB Upper17.02 USD
BB Middle14.70 USD
BB Lower12.37 USD
BB Width31.64%
ATR (14)1.026 USD
Vol Ratio (20d)0.98x